Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. As a biotechnology company developing and commercializing therapies for gastrointestinal (GI) and rare diseases, Ironwood uses these filings to report on its financial condition, collaboration revenues from LINZESS® (linaclotide), progress of its apraglutide program, capital structure and risk factors.
In its annual reports on Form 10-K, Ironwood presents audited financial statements, management’s discussion and analysis of results, details on its GI and rare disease portfolio, and information about collaborations with partners such as AbbVie, Astellas and AstraZeneca. These filings also describe material weaknesses in internal control over financial reporting identified as of December 31, 2024, and the company’s efforts to address them.
Quarterly reports on Form 10-Q update investors on interim financial performance, including collaboration revenue tied to LINZESS U.S. net sales, research and development expenses related to apraglutide and other programs, restructuring charges, interest expense on convertible senior notes and revolving credit facilities, and non-GAAP measures such as adjusted EBITDA and non-GAAP net income or loss.
Current reports on Form 8-K provide timely disclosure of specific events. For Ironwood, 8-K filings in 2025 have covered topics such as Nasdaq notifications about bid price and filing timeliness, the company’s receipt of a Maximum Fair Price determination for LINZESS under the Inflation Reduction Act, changes in the independent registered public accounting firm, director resignations, and the public release of quarterly earnings press releases.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents, such as shifts in financial guidance, updates on the apraglutide regulatory path, or changes in collaboration economics. Users can quickly identify information related to annual reports (10-K), quarterly reports (10-Q) and current reports (8-K), and can review disclosures that affect listing status, internal controls, and major GI and rare disease programs.
This page also helps investors monitor governance and compliance developments, including responses to Nasdaq listing rules and auditor changes, alongside the financial and operational data that shape the IRWD investment profile.
The Vanguard Group filed Amendment No. 5 to Schedule 13G/A reporting zero beneficial ownership of Ironwood Pharmaceuticals Inc. common stock. The filing states an internal realignment effective January 12, 2026 resulted in certain Vanguard subsidiaries reporting separately, and Vanguard no longer reports beneficial ownership of those subsidiary holdings.
The amendment identifies The Vanguard Group as the filer and shows 0 shares and 0% ownership; the form is signed by Ashley Grim on 03/27/2026.
Sarissa Capital Management LP and Alexander J. Denner filed Amendment No. 4 to their Schedule 13D for Ironwood Pharmaceuticals. The filing reports that Sarissa Capital may be deemed to beneficially own 9,188,635 shares, or approximately 5.6% of Ironwood’s Class A common stock.
Dr. Denner may be deemed to beneficially own 9,444,944 shares, representing about 5.8% of the outstanding shares, including those held through Sarissa-managed funds and those he holds directly as a director. On March 17, 2026, Sarissa Funds sold 6,725,000 shares at a weighted average price of $3.0501 per share and 5,800 shares at $3.3084 per share, for aggregate proceeds of $20,511,923 and $19,189, respectively.
On the same date, Dr. Denner was granted 4,451 shares in his capacity as a director of Ironwood. The filing states that, other than these transactions, no other transactions in the shares were effected by the reporting persons during the prior 60 days as of the afternoon of March 19, 2026.
IRONWOOD PHARMACEUTICALS INC director-related entities reported major share sales alongside a small equity grant. Investment vehicles advised by Sarissa Capital Management LP sold a total of 6,730,800 shares of Class A Common Stock on March 17, 2026 in open-market transactions at prices between $3.05 and $3.31 per share, leaving 9,188,635 shares held indirectly. Separately, Dr. Alexander J. Denner received a grant of 4,451 shares on March 13, 2026 under the company’s non-employee director compensation policy, bringing his directly held shares to 256,309. Footnotes state Sarissa Capital and its funds directly hold the sold and remaining indirect shares, with each party, including Dr. Denner, disclaiming beneficial ownership beyond their pecuniary interest.
Ironwood Pharmaceuticals Chief Legal Officer John Minardo received an equity grant of 136,612 shares of Class A Common Stock as a stock award. The shares were acquired at no cash cost to him as a grant or award, rather than an open-market purchase.
The award was granted in the form of restricted stock units as an annual performance award and will vest in four equal installments, with 25% of the underlying shares vesting on each approximate anniversary of the grant date. Following this grant, Minardo directly holds a total of 500,498 shares of Class A Common Stock.
Ironwood Pharmaceuticals reported that Chief Financial Officer Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. The award is structured as restricted stock units granted as an annual performance award.
The award vests in four equal installments, with 25% of the shares vesting on each approximate anniversary of the grant date. Following this grant, Martini directly holds 297,213 shares of Class A Common Stock. This is a compensation-related acquisition, not an open-market purchase or sale.
Gaskins Tammi L reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC reported that Chief Commercial Officer Tammi L. Gaskins received an equity grant of 136,612 shares of Class A Common Stock in the form of restricted stock units. These units were granted at no cash cost and represent a compensation award rather than an open-market purchase.
The award, described as an annual performance grant, vests in four equal installments of 25% on each approximate anniversary of the grant date, tying value to continued service and performance over time. Following this grant, Gaskins’ direct holdings increased to 350,350 shares of Class A Common Stock.
Shetzline Michael reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals reported that SVP and Chief Medical Officer Michael Shetzline received a grant of 136,612 shares of Class A Common Stock as an annual performance-related restricted stock unit award. The grant has no purchase price and will vest in 25% increments on each approximate anniversary of the grant, leaving him with 658,037 shares directly owned after the award.
Silver Ronald reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals’ principal accounting officer Ronald Silver received a stock-based compensation grant. He was awarded 163,934 shares of Class A Common Stock as restricted stock units, with no cash paid per share. The award vests in four equal annual installments. Following this grant, he directly holds 416,570 shares.
MCCOURT Thomas A reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC reported that Chief Executive Officer Thomas A. McCourt received a grant of 409,836 shares of Class A Common Stock as a restricted stock unit award. This annual performance award vests in three equal installments of 33.33% on each approximate anniversary of the grant.
Following this award, McCourt directly holds 1,898,838 shares of Class A Common Stock. The grant is compensation-related and was recorded at no cash purchase price per share.
Ironwood Pharmaceuticals, Inc. reported that it has met the liquidity conditions tied to the “Maturity Date” definition in its existing Credit Agreement with Wells Fargo Bank, National Association, as administrative agent. As a result, the revolving credit facility’s maturity date remains December 31, 2028, under the current terms of the Credit Agreement.